{"organizations": [], "uuid": "d51783864a47281810fca2096926160bbdda3a8d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/24/globe-newswire-supernus-to-host-first-quarter-2018-earnings-conference-call.html", "country": "US", "domain_rank": 767, "title": "Supernus to Host First Quarter 2018 Earnings Conference Call", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.153, "site_type": "news", "published": "2018-04-25T00:15:00.000+03:00", "replies_count": 0, "uuid": "d51783864a47281810fca2096926160bbdda3a8d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/24/globe-newswire-supernus-to-host-first-quarter-2018-earnings-conference-call.html", "ord_in_thread": 0, "title": "Supernus to Host First Quarter 2018 Earnings Conference Call", "locations": [], "entities": {"persons": [{"name": "jack khattar", "sentiment": "none"}, {"name": "greg patrick", "sentiment": "none"}], "locations": [{"name": "md.", "sentiment": "none"}, {"name": "rockville", "sentiment": "none"}], "organizations": [{"name": "supernus pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ROCKVILLE, Md., Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2018 after 5:00 p.m. ET on Tuesday, May 8, 2018.\nJack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to discuss the first quarter 2018 business results on Wednesday, May 9, 2018 at 9:00 a.m. ET. Following management’s prepared discussion and analysis, the call will be open for questions.\nA live webcast will be available at www.supernus.com .\nPlease refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.\nConference dial-in: (877) 288-1043 International dial-in: (970) 315-0267 Conference ID: 1568978 Conference Call Name: Supernus Pharmaceuticals First Quarter 2018 Earnings Conference Call Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.\nAbout Supernus Pharmaceuticals, Inc.\nSupernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.\nCONTACTS:\nJack A. Khattar, President and CEO\nGregory S. Patrick, Vice President and CFO\nSupernus Pharmaceuticals, Inc.\nTel: (301) 838-2591\nor\nINVESTOR CONTACT:\nPeter Vozzo\nWestwicke Partners\nOffice: (443) 213-0505\nMobile: (443) 377-4767\nEmail: peter.vozzo@westwicke.com\nSource:Supernus Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=EzrTsvWTxZLFfYrVz5YFmmcC8Uursi-DoAgs3_BWQ8avssywbG8zz_PrSbe7ra32pNXPdjyMbn5ofv_4eXvdEv79-lxdPb9mvpxNl4eWU10=", "https://www.globenewswire.com/Tracker?data=URvR40ZrGVShLlf_pfbTA18_AYLJZRg9WQfJd6tsZKxFDQv2JzehIHF1vxvNllukUonkuXyGr3bxPEPBFLk6SA==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/1fc58442-511b-40c2-a8c0-f1e78b8437b4"], "published": "2018-04-25T00:15:00.000+03:00", "crawled": "2018-04-25T00:43:55.029+03:00", "highlightTitle": ""}